secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001213900-24-001894
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell reports Q4 2023 product sales of $5.1M, up 30% YoY; backlog grows to $9.4M
--------------------------------------------------------------------------------

- Q4 2023 sales $5.1M vs $3.9M in Q4 2022 (+30.3%); full-year 2023 sales $17.5M vs $18.6M (-5.9%).
- Backlog $9.4M as of Dec 31, 2023, up from $2.5M a year ago, driven by production disruptions from contamination events.
- Production output improved in Nov/Dec 2023, annualizing ~$26.8M; company targeting >$6M quarterly production.
- FDA response on Re-Tain CMC Technical Section expected by May 2024.
- Conference call to discuss full results on Feb 22, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000121390024001894/0001213900-24-001894-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000121390024001894/ea191339-8k_immucell.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-001894

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer